Provided by Tiger Trade Technology Pte. Ltd.

Bristol-Myers Squibb

60.66
+0.36000.60%
Post-market: 60.890.2300+0.38%17:25 EST
Volume:9.60M
Turnover:581.09M
Market Cap:123.49B
PE:17.53
High:60.93
Open:60.62
Low:59.65
Close:60.30
52wk High:63.33
52wk Low:42.52
Shares:2.04B
Float Shares:2.03B
Volume Ratio:0.79
T/O Rate:0.47%
Dividend:2.49
Dividend Rate:4.11%
EPS(TTM):3.46
EPS(LYR):3.46
ROE:40.44%
ROA:10.29%
PB:6.68
PE(LYR):17.53

Loading ...

BMY’s Mavacamten Safety Extension Wraps Up, Sharpening the Long-Term Outlook in Hypertrophic Cardiomyopathy

TIPRANKS
·
5 hours ago

Bristol-Myers Squibb Initiated at Overweight by Barclays

Dow Jones
·
Yesterday

Daiwa Securities Adjusts Price Target on Bristol-Myers Squibb to $62 From $43, Maintains Neutral Rating

MT Newswires Live
·
Yesterday

Daiichi Sankyo Names John Tsai Global Head of R&D

Reuters
·
Yesterday

Texas sues Sanofi for allegedly 'bribing' providers to boost drug prescriptions

Reuters
·
Yesterday

Prothena Q4 net loss narrows

Reuters
·
Yesterday

Prothena Q4 FY2025 revenue hits USD 0.02m and FY2025 net loss totals USD 244.09m

Reuters
·
Yesterday

Bristol Myers Squibb Co. Stock Underperforms Wednesday When Compared To Competitors

Dow Jones
·
Feb 19

BRIEF-Evinova Announces Strategic Collaborations With Astellas, Astrazeneca & Bristol Myers Squibb

Reuters
·
Feb 18

BRIEF-Mubadala Investment Co Pjsc Reports Share Stake In Pfizer, Abbvie, Dissolves in Merck, Dell

Reuters
·
Feb 18

Bristol-Myers Squibb Co: U.S. FDA Assigns a Target Action Date of August 17, 2026, Grants Breakthrough Therapy Designation & Priority Review

THOMSON REUTERS
·
Feb 17

Balanced Risk-Reward Keeps Bristol-Myers Squibb Rated Hold as CELMoD Franchise Awaits Key Iberdomide Data

TIPRANKS
·
Feb 17

FDA Accepts Bristol Myers Squibb Application for Iberdomide in Multiple Myeloma

Reuters
·
Feb 17

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma

THOMSON REUTERS
·
Feb 17

Bristol-Myers Squibb Co - FDA Assigns Pdufa Date of August 17, 2026

THOMSON REUTERS
·
Feb 17

Bristol Myers Squibb Co. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Feb 14

Bristol Myers’ treatment of follicular lymphoma granted FDA orphan designation

TIPRANKS
·
Feb 14

BMY-Backed Milvexian Stroke Trial Moves Forward, Keeping Upside Optionality Alive

TIPRANKS
·
Feb 14

Bristol-Myers Squibb Expands Real-World MDS Footprint in Asia With New Registry Study

TIPRANKS
·
Feb 14

Bristol-Myers Squibb: Solid Near-Term Execution and 2026 EPS Boost from Eliquis, but Limited Long-Term Visibility Supports Hold Rating

TIPRANKS
·
Feb 10